3 recruiting, 2 completed, 2 not yet recruiting, 1 active not recruiting. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 3, Completed 2, Not yet recruiting 2, Active not recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Pluvicto: new trials by email Literature Review of Pluvicto trials Research Report on Pluvicto
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Lu-177 PSMA Treatment in Cell Renal Carcinoma Lu-177 PSMA-617 - Metastatic Renal Cancer | Phase 3 | Not yet recruiting | Ankara University | 20 | 2026-05-01 | 2026-02-27 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2026-03-31 | 2026-11-03 |
| Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) 177Lu-PMSA-617, Standard of Care - Prostate Cancer Metastatic | Phase 3 | Recruiting | UNICANCER | 500 | 2024-09-12 | 2024-12-20 |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT) - Prostate Cancer Metastatic | Phase 3 | Recruiting | University College, London | 3360 | 2024-06-11 | 2025-09-26 |
| 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Completed | Novartis Pharmaceuticals | 469 | 2021-06-15 | 2026-11-04 |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 1144 | 2021-06-09 | 2026-11-04 |
| Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer 177Lu-PSMA-617, Best supportive/best standard of care - Prostate Cancer | Phase 3 | Completed | Endocyte | 861 | 2018-05-29 | 2025-01-13 |
Prostatic Neoplasms (5) · Carcinoma, Renal Cell (1) · Genital Diseases, Male (1) · Kidney Neoplasms (1) · Prostatic Diseases (1)
Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Ankara University (1) · ECOG-ACRIN Cancer Research Group (1) · Endocyte (1) · UNICANCER (1) · University College, London (1)
France (4) · United Kingdom (4) · United States (4) · Belgium (3) · Canada (3) · Germany (3) · Netherlands (3) · Sweden (3) · Austria (2) · Czechia (2) · Denmark (2) · Poland (2) · Spain (2) · Switzerland (2) · China (1)
Louise Brown (1) · Michael Schweizer (1) · Nick James (1) · Thomas Hope, MD (1)
PMID 31595044, PMID 33189510, PMID 34161051, PMID 37230533, PMID 37269841, PMID 38050121, PMID 38185538, PMID 38534939, PMID 39031642, PMID 39162634, PMID 39242323, PMID 39293462, PMID 39430616, PMID 40441170, PMID 40680993, PMID 41979224, PMID 42561994
2023 (2), 2018 (1), U10CA180820 (1)